Maverick Capital’s GSK GSK Stock Holding History

Maverick Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-22,816	Closed	-$1.16M	–	140
2016 Q1	$1.16M	Buy	+22,816	New	+$1.14M	0.02%	94

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Maverick Capital's GSK Position: Q2 2016 in Review

Maverick Capital sold out of GSK (GSK) in Q2 2016, closing a stake of 22,816 shares — an estimated $1.16M sold.

Maverick Capital first reported a position in GSK in Q1 2016 and held it in 1 quarter. The position peaked at $1.16M in Q1 2016. 741 funds tracked by Wall St. Rank hold GSK as of Q2 2016.

Maverick Capital reported no remaining GSK position as of Q2 2016 after selling out during the quarter.
Maverick Capital sold 22,816 GSK shares in Q2 2016, an estimated $1.16M.
Maverick Capital first reported a position in GSK in Q1 2016 and held it in 1 quarter.
Maverick Capital's GSK position peaked at $1.16M in Q1 2016.
741 funds tracked by Wall St. Rank held GSK as of Q2 2016.

Based on Maverick Capital's 13F filing for Q2 2016, filed 15 Aug 2016.